Status and phase
Conditions
Treatments
About
The investigators like to learn whether Lidoderm patch (lidocaine 5%) helps tinnitus patients.
so far it is known that lidocaine I.V do helps tinnitus but until now it is not clear if other means of drug delivery (e.g lidocaine patch) help tinnitus.
The investigators are going to compare 1 day of treatment with lidoderm patch cream Versus (VS.) tegaderm patch (containing no drug) in treating tinnitus patients.
Full description
The purpose of the study is to investigate whether lidoderm patch (lidocain 5% patch) cream decreases tinnitus by comparing pretrial questionnaires to post trial questionnaires.
first the investigators are going to invite tinnitus patients for the first visit.
the participants will get full explanation about the trial. in the first visit the investigators will confirm that the participants are suitable for the trial -
no exclusion criteria are present
the participant will perform 2 screening tests-
the participant will undergo ear investigation to exclude ear inflammation, perform audiometry and tinnitus characteristic test to prove sensorineural hearing loss and to get details about the tinnitus characteristics. then the participant will fill 4 questionnaires that reflect the tinnitus loudness and show how much the participant does suffer from this conditions.
Later that day (in the evening), the participant will come to the department (second visit) and the ear nose and throat (ENT) doctor will attach 3 patches on his back for 12 hours (either lidoderm or tegaderm patches).
The participant will be instructed to call the chief investigator When any kind of side effect occurs (topical/ systemic).
in the next morning the participant will come back to our department. (third visit) he will-
The investigators hypotheses that lidoderm patches decreases tinnitus as can be estimated by the score of the 4 questionnaires that measure tinnitus aspects.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
58 participants in 2 patient groups
Loading...
Central trial contact
Miki Paker, MD; Salim Mazzawi, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal